IRF-4 Suppresses BCR/ABL Transformation of Myeloid Cells in a DNA Binding-independent Manner

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2011 Nov 24

PMID 22110133

Citations 5

Authors

Seung-Hee Jo

Ruibao Ren

Affiliations

Soon will be listed here.

Abstract

Interferon regulatory factor 4 (IRF-4) is essential for B and T cell development and immune response regulation, and has both nuclear and cytoplasmic functions. IRF-4 was originally identified as a proto-oncogene resulting from a t(6;14) chromosomal translocation in multiple myeloma and its expression was shown to be essential for multiple myeloma cell survival. However, we have previously shown that IRF-4 functions as a tumor suppressor in the myeloid lineage and in early stages of B cell development. In this study, we found that IRF-4 suppresses BCR/ABL transformation of myeloid cells. To gain insight into the molecular pathways that mediate IRF-4 tumor suppressor function, we performed a structure-function analysis of IRF-4 as a suppressor of BCR/ABL transformation. We found that the DNA binding domain deletion mutant of IRF-4, which is localized only in the cytoplasm, is still able to inhibit BCR/ABL transformation of myeloid cells. IRF-4 also functions as a tumor suppressor in bone marrow cells deficient in MyD88, an IRF-4-interacting protein found in the cytoplasm. However, IRF-4 tumor suppressor activity is lost in IRF association domain (IAD) deletion mutants. These results demonstrate that IRF-4 suppresses BCR/ABL transformation by a novel cytoplasmic function involving its IAD domain.

Citing Articles

Epstein-Barr Virus: Diseases Linked to Infection and Transformation.

Jha H, Pei Y, Robertson E Front Microbiol. 2016; 7:1602.

PMID: 27826287 PMC: 5078142. DOI: 10.3389/fmicb.2016.01602.

Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.

So A, Sookram R, Chaudhuri A, Minisandram A, Cheng D, Xie C Blood. 2014; 124(9):1502-12.

PMID: 25006123 PMC: 4148772. DOI: 10.1182/blood-2014-02-553842.

Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4.

Ma S, Shukla V, Fang L, Gould K, Joshi S, Lu R J Biol Chem. 2013; 288(37):26430-40.

PMID: 23897826 PMC: 3772189. DOI: 10.1074/jbc.M113.475913.

The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.

Banerjee S, Lu J, Cai Q, Saha A, Jha H, Dzeng R PLoS Pathog. 2013; 9(5):e1003314.

PMID: 23658517 PMC: 3642079. DOI: 10.1371/journal.ppat.1003314.

Reply to MacLeod et al.: Multiple myeloma plasma cells have chameleon characteristics.

Breitkopf S, Yuan M, Pihan G, Asara J Proc Natl Acad Sci U S A. 2013; 110(4):E272.

PMID: 23463875 PMC: 3557032. DOI: 10.1073/pnas.1220582110.

References

Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F . Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996; 87(2):307-17. DOI: 10.1016/s0092-8674(00)81348-3. View

Acquaviva J, Chen X, Ren R . IRF-4 functions as a tumor suppressor in early B-cell development. Blood. 2008; 112(9):3798-806. PMC: 2572804. DOI: 10.1182/blood-2007-10-117838. View

Thomas E, Cancelas J, Zheng Y, Williams D . Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia. 2008; 22(5):898-904. PMC: 4464749. DOI: 10.1038/leu.2008.71. View

Brass A, Zhu A, Singh H . Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J. 1999; 18(4):977-91. PMC: 1171190. DOI: 10.1093/emboj/18.4.977. View

Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T . Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature. 2005; 434(7030):243-9. DOI: 10.1038/nature03308. View

Klein F, Feldhahn N, Mooster J, Sprangers M, Hofmann W, Wernet P . Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2004; 174(1):367-75. DOI: 10.4049/jimmunol.174.1.367. View

Gupta S, Fanzo J, Hu C, Cox D, Jang S, Lee A . T cell receptor engagement leads to the recruitment of IBP, a novel guanine nucleotide exchange factor, to the immunological synapse. J Biol Chem. 2003; 278(44):43541-9. DOI: 10.1074/jbc.M308960200. View

Hao S, Ren R . Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol. 2000; 20(4):1149-61. PMC: 85233. DOI: 10.1128/MCB.20.4.1149-1161.2000. View

Johnson K, Hashimshony T, Sawai C, Pongubala J, Skok J, Aifantis I . Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity. 2008; 28(3):335-45. DOI: 10.1016/j.immuni.2007.12.019. View

10.

Sciammas R, Shaffer A, Schatz J, Zhao H, Staudt L, Singh H . Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006; 25(2):225-36. DOI: 10.1016/j.immuni.2006.07.009. View

11.

Ma S, Pathak S, Trinh L, Lu R . Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. Blood. 2007; 111(3):1396-403. PMC: 2214771. DOI: 10.1182/blood-2007-08-110106. View

12.

Huang B, Zhao J, Unkeless J, Feng Z, Xiong H . TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008; 27(2):218-24. DOI: 10.1038/sj.onc.1210904. View

13.

Mamane Y, Sharma S, Petropoulos L, Lin R, Hiscott J . Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity. 2000; 12(2):129-40. DOI: 10.1016/s1074-7613(00)80166-1. View

14.

Ortmann C, Burchert A, Holzle K, Nitsche A, Wittig B, Neubauer A . Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res. 2006; 33(21):6895-905. PMC: 1310901. DOI: 10.1093/nar/gki1001. View

15.

Iida S, Rao P, Butler M, Corradini P, Boccadoro M, Klein B . Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997; 17(2):226-30. DOI: 10.1038/ng1097-226. View

16.

Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A . Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001; 97(11):3648-50. DOI: 10.1182/blood.v97.11.3648. View

17.

Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K . Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A. 2005; 102(44):15989-94. PMC: 1257749. DOI: 10.1073/pnas.0508327102. View

18.

Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5(3):172-83. DOI: 10.1038/nrc1567. View

19.

Ito M, Iida S, Inagaki H, Tsuboi K, Komatsu H, Yamaguchi M . MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res. 2002; 93(6):685-94. PMC: 5927045. DOI: 10.1111/j.1349-7006.2002.tb01307.x. View

20.

Jo S, Schatz J, Acquaviva J, Singh H, Ren R . Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood. 2010; 116(15):2759-67. PMC: 2974585. DOI: 10.1182/blood-2009-07-234559. View